Oligodendrocyte subtype diversity underlines clinical progression in Parkinson’s disease
Oligodendrocyte subtype diversity underlines clinical progression in Parkinson’s disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Publication status: preprint
A plain-language reading has not been prepared for this paper yet.
Original abstract
ABSTRACT Despite growing evidence for glial involvement in Parkinson’s disease, oligodendrocyte dysfunction remains poorly defined. To address this gap, we compared single-cell RNA sequencing from a mouse model of α-synuclein aggregation pathology with fresh human brain tissue from deep brain stimulation surgery to build a cross-species framework of disease progression. In total, we profiled over 200,000 cortical transcriptomes, including 55,000 oligodendrocytes. Early disease in mice was characterized by inflammatory activation, while advanced stages in both species converged on metabolic dysfunction, including impaired ribosomal output, chaperone stress responses, ubiquitination deficits, and lysosomal perturbation. In patients, APLP1 was upregulated and correlated with clinical disease progression and increased levodopa demand, linking α-synuclein spread in oligodendrocytes to disease severity. APP and CNTN pathways emerged as key signalling axes, with CNTN reflecting weakened reparative communication and reduced resilience. Together, these findings define oligodendrocyte subtype dynamics as shared and clinically relevant features of PD progression.